DOI:
10.1055/s-00000142
Frauenheilkunde up2date
LinksClose Window
References
Moore KN, Martin LP, OʼMalley DM. et al.
Safety and activity of mirvetuximab soravtansine (IMGN853), a folate receptor alpha-targeting antibody-drug conjugate, in platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer: A phase I expansion study.
J Clin Oncol 2017;
35: 1112-1118
Access:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.